The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 24, 2024

Filed:

Mar. 04, 2019
Applicant:

New York University, New York, NY (US);

Inventors:

Daniel Meruelo, Scarborough, NY (US);

Alicia Hurtado Martinez, New York, NY (US);

Christine Pampeno, New York, NY (US);

Iris Scherwitzl, New York, NY (US);

Assignee:

New York University, New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C12N 7/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 14/70578 (2013.01); C12N 7/00 (2013.01); A61K 2039/5256 (2013.01); C07K 2319/055 (2013.01); C07K 2319/30 (2013.01); C12N 2770/36132 (2013.01); C12N 2770/36143 (2013.01);
Abstract

Provided are polynucleotides and viral vectors, particularly,vectors such as Sindbis viral vectors, which encode an immune checkpoint protein, or a ligand binding portion of the checkpoint protein, or an immune checkpoint protein or ligand binding portion thereof fused to one or more immunoglobulin (Ig) domains, e.g., an Ig hinge region and an Ig heavy chain constant domain. Methods of treating a mammalian subject having a cancer or tumor are provided, in which the viral vectors, e.g., a Sindbis virus vector, encoding the immune checkpoint protein, a ligand binding portion thereof, or a checkpoint protein fusion protein as described, are administered to the subject, resulting in an anti-cancer or anti-tumor immune response, significant reduction in tumor growth in the treated subject and increased survivability.


Find Patent Forward Citations

Loading…